Compare Ascendis Pharma A/S (ASND) vs KB Financial Group, Inc. (KB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs KB Financial Group, Inc. — how do they compare? Ascendis Pharma A/S trades at $265.33 (market cap $17.74B), while KB Financial Group, Inc. trades at $123.62 (market cap $42.55B). The key difference: KB Financial Group, Inc. is far larger — about 2.4× Ascendis Pharma A/S's market cap, and KB Financial Group, Inc. pays a 2.55% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | KB | |
|---|---|---|
Market Cap | $17.74B | $42.55B |
Sector | Health | Financials |
52-Week High | $277.18 | $123.19 |
52-Week Low | $163.32 | $77.50 |
Enterprise Value | $18.11B | — |
Dividend Yield | — | 2.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
KB Financial Group (KB) trades at $123.19, up 6.78% today, showing strong momentum with consistent earnings beats in recent quarters. The stock exhibits bullish technical signals from moving averages, though oscillators suggest caution with RSI near overbought levels. Fundamentally, revenue grew to $21.23T in 2025 with a net income margin of 27.82%, supported by diversification into non-banking segments. Analyst sentiment is mixed with a 33% buy rating, while recent news highlights dividend potential and non-banking growth.
The outlook for KB remains positive due to earnings growth and strategic diversification, but risks include reliance on interest income and macroeconomic sensitivity. Near-term resistance at $121 could limit upside, while support at $112 provides a cushion. Institutional holdings and dividend focus offer stability, yet investors should monitor interest rate impacts and competitive pressures in the banking sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About KB Financial Group, Inc.
KB Financial is the parent company of KB Kookmin Bank, Korea's largest commercial bank, with a 13.1% share of loans as of 2021. Its predecessor banks were established in the 1960s as government policy banks and privatized in the 1990s. Its credit card subsidiary KB Kookmin Card is the number-three player behind Shinhan Card and Samsung Card. KB has in recent years expanded its nonbank business by buying LIG Insurance and Hyundai Securities, making KB a top-five player in nonlife insurance and in securities, and most recently by buying Prudential Life Insurance Korea. It also has KB Capital, which provides leasing and installment finance.
Read more on KB →
